We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Self-Cleaning Mask with Antimicrobial Technology Deactivates 99% of Coronavirus Suspension in Minutes

By HospiMedica International staff writers
Posted on 15 Jul 2020
Scientists have confirmed that a new surgical mask having an outer layer with interactive antimicrobial protection can deactivate >99% of the coronavirus suspension in minutes.

Scientists at the University of Toronto (Toronto, Canada) have tested and established that the SARS-CoV-2 virus cannot be recovered after being applied to i3 BioMedical Inc.’s (Quebec, Canada) TrioMed Active mask as its external surface deactivates >99% of the coronavirus suspension within minutes.

Previous studies have established that people touch their face 23 times per hour on average and that the coronavirus remains present and infectious on the outer layer of masks for up to seven days. More...
In addition to the warnings issued by governmental authorities pertaining to self-contamination by touching one's mask, these studies further demonstrate the major deficiency in the level of protection for all wearers of current masks.

The TrioMed Active Mask type IIR surgical mask incorporates TrioMed's technology and provides an advanced level of active protection for healthcare workers and the general population. The patented antimicrobial technology is at the core of the company's entire line of medical products such as wound dressings, medical tapes, gloves, headwear, gowns and other personal protective equipment sold globally. The active antimicrobial protection of the mask’s outer layer deactivates >99% of the coronavirus SARS 2 and influenza virus H1N1. The TrioMed Active Mask type IIR surgical mask has viral filtration efficiency (VFE) of > 99.9% and bacterial filtration efficiency (BFE) of > 99.9%.

"The TrioMed Active Mask is the first and only respiratory protection that is scientifically proven to deactivate the virus causing COVID-19, therefore drastically reducing the risk of contamination for the wearer", said Pierre Jean Messier, founder and CEO of i3 Biomedical Inc. "Our company spent years and millions of dollars to develop this interactive antimicrobial technology. The resulting products are used by the medical community around the world and have been tested by independent laboratories to kill numerous microbes, such as MRSA, VRE, E-Coli, Staphylococcus Aureus, Influenza Virus and now SARS-CoV-2. This third-party scientific testing confirms TrioMed's leading position in medical antimicrobial technology available in the global fight against COVID-19."

Related Links:
i3 BioMedical Inc.
University of Toronto



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.